clinical trials

News

ACC25: Mineralys' uncontrolled hypertension drug aces trial

Mineralys looks odds on to become the first drug developer to bring an aldosterone synthase inhibitor to market for uncontrolled hypertension.

R&D

The time is right for a grand resurgence of commercial clini...

In the dark days of 2020, amid the global race for a COVID-19 vaccine, the UK showcased its world-class expertise in medical research.

R&D

Revolutionising personalised medicine: How IRT platforms are...

Cell and gene therapies offers transformative benefits to patients, including revolutionary treatment potential for cancer, AIDS, and hereditary diseases.

News

ACC25: Ozempic shows its value in PAD

Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.

News

ACC25: Positive results with Lilly's Lp(a)-lowering drug

Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.

News

MSD says subcutaneous Keytruda matches IV form

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial.

ACC25: Mineralys' uncontrolled hypertension drug aces trial

The time is right for a grand resurgence of commercial clini...

Revolutionising personalised medicine: How IRT platforms are...

ACC25: Ozempic shows its value in PAD

ACC25: Positive results with Lilly's Lp(a)-lowering drug

MSD says subcutaneous Keytruda matches IV form

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks